Comparative Pharmacology
Head-to-head clinical analysis: LAMIVUDINE NEVIRAPINE ZIDOVUDINE TABLETS versus LAMIVUDINE ZIDOVUDINE ABACAVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMIVUDINE NEVIRAPINE ZIDOVUDINE TABLETS versus LAMIVUDINE ZIDOVUDINE ABACAVIR.
LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE TABLETS vs LAMIVUDINE; ZIDOVUDINE; ABACAVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase by competing with natural substrates and causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing conformational disruption. Zidovudine is an NRTI that inhibits viral reverse transcriptase after intracellular phosphorylation to its active triphosphate form.
Lamivudine, zidovudine, and abacavir are nucleoside reverse transcriptase inhibitors (NRTIs). They are phosphorylated intracellularly to active metabolites that compete with natural nucleotides for incorporation into viral DNA, causing chain termination and inhibition of HIV reverse transcriptase.
One tablet (150 mg lamivudine/200 mg nevirapine/300 mg zidovudine) orally twice daily.
One tablet (300 mg abacavir, 150 mg lamivudine, 300 mg zidovudine) orally twice daily.
None Documented
None Documented
Lamivudine: 5-7h (adults), prolonged in renal impairment. Nevirapine: 25-30h (single dose), 40-45h (multiple doses, autoinduction). Zidovudine: 0.5-3h (terminal), prolonged in hepatic impairment.
Lamivudine: 5-7 hours (single dose), prolonged to ~11 hours in renal impairment; Zidovudine: 1.1 hours (terminal), increased to 1.4 hours in hepatic impairment; Abacavir: 1.5 hours (terminal), slightly prolonged in hepatic impairment; Clinical context: Dosing interval of 12 hours requires therapeutic drug monitoring in renal/hepatic dysfunction.
Lamivudine: ~70% renal (glomerular filtration and tubular secretion, unchanged). Nevirapine: ~80% biliary/fecal (metabolites), ~10% renal (unchanged). Zidovudine: ~75% renal (metabolism to glucuronide, tubular secretion).
Lamivudine: ~70% excreted unchanged in urine via glomerular filtration and active tubular secretion; Zidovudine: ~75% excreted as metabolites (primarily 5'-glucuronide) in urine, with <20% unchanged; Abacavir: ~83% excreted as metabolites in urine (via alcohol dehydrogenase and glucuronidation) and ~16% in feces; Total renal elimination accounts for >80% of clearance for all three components.
Category A/B
Category A/B
NRTI
NRTI